Allergen-specific circulating CLA+ memory T cells stratify IL-22 response in atopic dermatitis skin
Authors:
Open Access
- 1 July 2025
- journal article
- immunology
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1599892
Abstract
Background: Current understanding of IL-22 in atopic dermatitis (AD) mostly relies on animal models, intracellular staining of polyclonally activated peripheral lymphocytes, and biological therapies.Methods: We evaluated the IL-22 response to house dust mite (HDM) extract in 58 patients with moderate-to-severe AD using a coculture system made of circulating memory cutaneous lymphocyte associated antigen (CLA)+/− T cells with autologous lesional epidermal cells. Additionally, we performed histological and gene expression analysis in lesional skin biopsies, assessed specific IgE levels in plasma, and together with the clinical features of the patients, were related to the IL-22 in vitro response.Results: HDM triggered heterogeneous IL-22 secretion in memory T cells, preferentially in the CLA+ subset, which enabled patient stratification into IL22 producers (IL22P, n=17) and non-producers (IL22NP, n=41). IL22P showed an increased degree of epidermal thickness, overexpression of IL22 in lesional skin areas, elevated specific IgE levels against HDM and SEB in plasma, and a higher proinflammatory profile compared to IL22NP.Conclusions: This is the first report showing that allergen-specific CLA+ T-cell-mediated IL-22 in vitro response functionally distinguish moderate-to-severe adult AD patients with specific clinical features and activated IL-22 pathway in their lesional skin, paving the way for the selection of patients that may benefit from IL-22-directed therapies.Keywords
This publication has 44 references indexed in Scilit:
- Emerging Biologic Therapies for the Treatment of Atopic DermatitisDrugs, 2024
- Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumabJournal of Allergy and Clinical Immunology, 2019
- Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trialJournal of the American Academy of Dermatology, 2018
- Skin-infiltrating, interleukin-22–producing T cells differentiate pediatric psoriasis from adult psoriasisJournal of the American Academy of Dermatology, 2017
- Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2/TH1 cell imbalance, whereas adults acquire CLA+ TH22/TC22 cell subsetsJournal of Allergy and Clinical Immunology, 2015
- Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell populationJournal of Allergy and Clinical Immunology, 2015
- Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitisJournal of Allergy and Clinical Immunology, 2012
- IL-22–producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17–producing TH17 T cellsJournal of Allergy and Clinical Immunology, 2009
- IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are notJournal of Molecular Medicine, 2009
- Anti-Staphylococcus aureus-specific IgE in atopic dermatitisJournal of Allergy and Clinical Immunology, 1986